DaShenLin Pharmaceutical Group Future Growth
Future criteria checks 3/6
DaShenLin Pharmaceutical Group is forecast to grow earnings and revenue by 24.9% and 16.7% per annum respectively. EPS is expected to grow by 25.1% per annum. Return on equity is forecast to be 17.5% in 3 years.
Key information
24.9%
Earnings growth rate
25.1%
EPS growth rate
Consumer Retailing earnings growth | 41.6% |
Revenue growth rate | 16.7% |
Future return on equity | 17.5% |
Analyst coverage | Good |
Last updated | 19 Nov 2024 |
Recent future growth updates
Recent updates
Take Care Before Diving Into The Deep End On DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233)
Sep 30DaShenLin Pharmaceutical Group Co., Ltd. Just Missed Earnings - But Analysts Have Updated Their Models
Sep 03DaShenLin Pharmaceutical Group (SHSE:603233) May Have Issues Allocating Its Capital
Aug 20Not Many Are Piling Into DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233) Stock Yet As It Plummets 27%
Jun 17Does DaShenLin Pharmaceutical Group (SHSE:603233) Have A Healthy Balance Sheet?
Jun 09Are Investors Undervaluing DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233) By 30%?
May 21Some May Be Optimistic About DaShenLin Pharmaceutical Group's (SHSE:603233) Earnings
May 06Investors Could Be Concerned With DaShenLin Pharmaceutical Group's (SHSE:603233) Returns On Capital
Apr 09Lacklustre Performance Is Driving DaShenLin Pharmaceutical Group Co., Ltd.'s (SHSE:603233) Low P/E
Mar 17Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 38,449 | 1,676 | 2,342 | 3,970 | 12 |
12/31/2025 | 32,730 | 1,414 | 2,053 | 3,546 | 12 |
12/31/2024 | 26,949 | 1,071 | 2,717 | 3,276 | 7 |
9/30/2024 | 26,539 | 850 | 1,488 | 3,202 | N/A |
6/30/2024 | 25,885 | 907 | 1,634 | 3,464 | N/A |
3/31/2024 | 25,336 | 1,068 | 2,049 | 3,648 | N/A |
12/31/2023 | 24,531 | 1,166 | 1,377 | 3,174 | N/A |
9/30/2023 | 24,154 | 1,287 | 2,055 | 4,160 | N/A |
6/30/2023 | 23,519 | 1,239 | 1,846 | 3,815 | N/A |
3/31/2023 | 22,518 | 1,148 | 2,529 | 3,843 | N/A |
12/31/2022 | 21,248 | 1,036 | 2,722 | 3,757 | N/A |
9/30/2022 | 19,222 | 896 | 1,260 | 2,411 | N/A |
6/30/2022 | 18,425 | 860 | 1,027 | 2,237 | N/A |
3/31/2022 | 17,377 | 835 | 384 | 1,708 | N/A |
12/31/2021 | 16,759 | 791 | 260 | 1,555 | N/A |
9/30/2021 | 16,446 | 1,013 | 682 | 1,833 | N/A |
6/30/2021 | 15,697 | 1,113 | 1,097 | 2,066 | N/A |
3/31/2021 | 15,280 | 1,122 | 1,286 | 2,145 | N/A |
12/31/2020 | 14,583 | 1,062 | 1,162 | 1,954 | N/A |
9/30/2020 | 13,593 | 1,014 | 1,430 | 1,966 | N/A |
6/30/2020 | 12,829 | 917 | 1,229 | 1,759 | N/A |
3/31/2020 | 11,925 | 799 | 1,225 | 1,779 | N/A |
12/31/2019 | 11,141 | 703 | 1,206 | 1,708 | N/A |
9/30/2019 | 10,601 | 674 | 1,172 | 1,462 | N/A |
6/30/2019 | 10,029 | 624 | 852 | 1,285 | N/A |
3/31/2019 | 9,404 | 569 | 613 | 1,119 | N/A |
12/31/2018 | 8,859 | 532 | 319 | 874 | N/A |
9/30/2018 | 8,421 | 522 | -118 | 663 | N/A |
6/30/2018 | 8,003 | 515 | N/A | 553 | N/A |
3/31/2018 | 7,718 | 505 | N/A | 511 | N/A |
12/31/2017 | 7,421 | 475 | N/A | 648 | N/A |
9/30/2017 | 6,992 | 462 | N/A | 545 | N/A |
6/30/2017 | 6,824 | 458 | N/A | 497 | N/A |
3/31/2017 | 6,545 | 433 | N/A | 502 | N/A |
12/31/2016 | 6,274 | 430 | N/A | 496 | N/A |
6/30/2016 | 5,681 | 427 | N/A | 406 | N/A |
3/31/2016 | 5,464 | 415 | N/A | 445 | N/A |
12/31/2015 | 5,265 | 395 | N/A | 469 | N/A |
12/31/2014 | 4,545 | 266 | N/A | 449 | N/A |
12/31/2013 | 3,707 | 197 | N/A | 288 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 603233's forecast earnings growth (24.9% per year) is above the savings rate (2.8%).
Earnings vs Market: 603233's earnings (24.9% per year) are forecast to grow slower than the CN market (26.1% per year).
High Growth Earnings: 603233's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 603233's revenue (16.7% per year) is forecast to grow faster than the CN market (13.8% per year).
High Growth Revenue: 603233's revenue (16.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 603233's Return on Equity is forecast to be low in 3 years time (17.5%).